A Retrospective Analysis of Rituximab Treatment for B Cell Depletion in Different Pediatric Indications
Background: Rituximab (RTX) is used in cancer therapy as well as in the treatment of autoimmune diseases and alloimmune responses after transplantation. It depletes the disease-causing B cells by binding to the CD (cluster of differentiation) 20 antigen. We evaluate different pediatric treatment pro...
Saved in:
Main Authors: | Merlin Wennmann (Author), Simone Kathemann (Author), Kristina Kampmann (Author), Sinja Ohlsson (Author), Anja Büscher (Author), Dirk Holzinger (Author), Adela Della Marina (Author), Elke Lainka (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of Tacrolimus C/D Ratio in the First Year After Pediatric Liver Transplantation
by: Benas Prusinskas, et al.
Published: (2021) -
Is Rituximab-Associated Hypogammaglobulinemia Always Linked to B-Cell Depletion?
by: Anthie Damianaki, et al.
Published: (2022) -
B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?
by: P. Sarzi-Puttini, et al.
Published: (2011) -
Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris
by: Katharina Boch, et al.
Published: (2022) -
Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)
by: V. Bruzzese, et al.
Published: (2011)